The United Arab Emirates has officially become the third nation to authorize the use of Miebo, a cutting-edge prescription eye drop developed by Bausch + Lomb to combat dry eye disease. This condition, which frequently causes blurred vision, burning, and persistent discomfort, has become increasingly common due to the prevalence of air-conditioned environments and prolonged digital screen use. By targeting tear evaporation, Miebo stands out as a unique therapeutic option that works to stabilize the tear film and restore visual comfort for those struggling with the daily impact of the disease.

The regulatory approval from the Emirates Drug Establishment was driven by promising results from two major clinical trials, GOBI and MOJAVE, which monitored over 1,200 participants. The data confirmed that patients experienced notable relief from both the physical symptoms and underlying signs of the condition. By fast-tracking this medication, the UAE continues to demonstrate its commitment to providing citizens with access to the latest global healthcare innovations, offering a much-needed solution for millions who find their quality of life hindered by chronic eye irritation.